Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study

The aims of this multicentric retrospective study were to assess in a real-world setting the effectiveness and safety of canagliflozin 100 mg/d (CANA100) as an add-on to the background antihyperglycemic therapy, and to evaluate the intensification of prior sodium–glucose co-transporter type 2 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorgojo-Martínez, Juan J., Gargallo-Fernández, Manuel A., Galdón Sanz-Pastor, Alba, Antón-Bravo, Teresa, Brito-Sanfiel, Miguel, Wong-Cruz, Jaime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408903/
https://www.ncbi.nlm.nih.gov/pubmed/32708943
http://dx.doi.org/10.3390/jcm9072275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408903/
https://www.ncbi.nlm.nih.gov/pubmed/32708943
http://dx.doi.org/10.3390/jcm9072275

Ejemplares similares